Safety and efficacy of direct‐acting antivirals for the treatment of chronic hepatitis C in a real‐world population aged 65 years and older

Abstract

The availability of direct-acting antiviral agents (DAA) regimens has expanded the pool of patients eligible for treatment. However, data on the virologic response and tolerability of DAAs in elderly patients are lacking. We evaluated the efficacy and safety of DAAs in patients with advanced fibrosis/cirrhosis in real-life practice with the focus on those aged ≥65 years. Between January and December 2015, all consecutive patients with HCV-related advanced fibrosis/cirrhosis treated with DAA at eleven tertiary referral centres in Emilia Romagna (Italy) were enrolled. Regimen choice was based on viral genotype and stage of disease, according to guidelines. The primary end point was sustained virologic response 12 weeks after the end of treatment (SVR12). Overall, 282 of 556 (50.7%) patients evaluated were elderly, most of them with cirrhosis. Antiviral therapy was stopped prematurely in four (1.4%) patients. Two patients, both with cirrhosis, died during treatment due to worsening of liver/renal function. SVR12 was achieved by 94.7% and was comparable to that obtained in patients aged <65 (P=.074). Similar data were also reported in subgroup of patients aged ≥75 years. All patients with advanced fibrosis achieved virologic response. SVR12 was 80.8% in Child-Pugh-Turcotte (CTP)-B cirrhosis and 95.4% in CTP-A (P=.013). According to genotype, the SVR12 was achieved in 172 of 181 (95%) with genotype 1b cirrhosis and in 44 of 48 (91.7%) with genotype 2 cirrhosis. In conclusions, in a real-world setting, DAAs are safe and effective in elderly patients with HCV-related advanced fibrosis/cirrhosis, but SVR12 is lower with worsening CTP class.

Direct‐acting antivirals for HCV treatment in older patients: A systematic review and meta‐analysis

“…Seven observational studies also included a subgroup analysis of patients over 75 years ; one observational study and one SAT reported data on patients older than 80 years …”

“…Safety outcomes were reported by 10 studies (1 RCT, 1 SAT and 8 observational studies) . The risk of bias of the included studies is shown in Table and .…”

Relative changes in handgrip strength and skeletal muscle volume in patients with chronic liver disease over a 2‐year observation period

“…Many viral CLD patients without CPS decline are treated with NA for HBV, and with IFN or DAA for HCV . However, the frequency of antiviral therapy, especially elimination of HCV by IFN or DAA in patients with CPS decline, was lower as compared to those without.…”

Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension

“…Recent progress in antiviral therapy, such as direct-acting antivirals 22,23 and nucleos(t)ide analogs, [24][25][26] has made prevention of CLD progression possible, although issues related to muscle wasting in CLD patients remain. It is also well known that many LC patients have protein-calorie malnutrition, 27,28 and it has been reported that a late evening snack (LES) may be useful for improving protein catabolism and lipolysis.…”